Three Drug Combinations in the Treatment of Fit Elderly Multiple Myeloma Patients.

ABSTRACT: The multiple myeloma (MM) non transplant eligible (NTE) population is growing in line with the aging of the population in Western countries. Historically, this population has been known for having a greater risk of treatment related toxicity, and therefore drug development was slow and rather oriented towards the improvement of safety profile than the optimization of disease control. However, NTE MM patients, at least for the fit/non frail patients in recent years, seemed to have benefited more from a less palliative care to improve the depth of response and then prolong survival. NTE MM being a quite heterogeneous population, there are still a number of groups of patients that are in need of more efficient therapy, avoiding unnecessary toxicity, particularly for the frail patients. The us

SUBMITTER: Gardeney H 

PROVIDER: S-EPMC7694236 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature